Katinger Gmbh

Apotex Inc.

Polymun Scientific Immunbiologische Forschung Gmbh

Thomas Hemetsberger

Hermann W Katinger

Robert Weik

Renate Kunert

Thomas Sterovsky

Heinz Redl

Jason Everett Dowd

A recombinant human monoclonal pentameric IgM antibody comprising the capability of oligospecific binding to purified ganglioside epitopes GD3, GM3, GD2 and GM1 and the capability of specific binding to malignant cancer cells selected from the group consisting of melanoma cells, small cell lung cancer cells, glioblastoma cells, and estrogen receptor-negative metastatic breast cancer cells; a cell line producing the IgM antibody; and the use of the IgM antibody as a diagnostic tool and/or as a therapeutic agent.

Recombinant human IgM-antibody effective against cancer cells

A method for purifying rHuEPO through the use of a multi-step filtration process which provides for a rHuEPO product having superior stability and shelf-life.

Enhanced liquid formulation stability of erythropoietin alpha through purification processing

The present invention relates to recombinant fusion proteins wherein erythropoietin (EPO) is linked via its C-terminus to an Fc fragment, and wherein the recombinant fusion proteins are further carbamoylated at the primary amines of the fusion protein. More specifically the invention relates to carbamoylated EPO-Fc fusion proteins, wherein at least one, preferably two or more, lysine amine residues and/or the N-terminal amino acid of the fusion protein are carbamoylated. The carbamoylated EPO-Fc fusion proteins of the present invention having a reduced hematopoietic activity whereas the tissue regenerative activity, i.e. the nerve cell regenerative activity remains unaltered or is even enhanced as compared to unmodified EPO-Fc fusion proteins. The invention further relates to a process for the manufacture of such fusion proteins and to pharmaceutical compositions containing them, as well as to the use of such fusion proteins and pharmaceutical compositions for medical therapy.

Carbamoylated EPO-Fc fusion proteins

Growing community of inventors

Klosterneuburg, Austria

Thomas Hemetsberger